Literature DB >> 19574000

The cost of treating addiction from the client's perspective: results from a multi-modality application of the Client DATCAP.

Kathryn E McCollister1, Michael T French, Jeffrey M Pyne, Brenda Booth, Richard Rapp, Carey Carr.   

Abstract

There is a considerable disparity between the number of individuals who need substance abuse treatment and the number who actually receive it. This is partly due to the fact that many individuals with substance use disorders do not perceive a need for formal treatment. Another contributing factor, however, is a discrepancy between the real and perceived cost of services. Although many cost evaluations of substance abuse treatment have been conducted from the treatment provider perspective, less is known about the client-specific costs of attending treatment (e.g., lost work and leisure time, transportation, out-of-pocket and in-kind payments). Concerns about financial and other barriers to participating in treatment have encouraged addiction researchers to more carefully consider these previously unmeasured costs. To address this information gap, we administered the Client Drug Abuse Treatment Cost Analysis Program (Client DATCAP) to 302 clients (representing a total of 302 outpatient and 142 inpatient treatment episodes) as part of a larger study examining the cost-effectiveness of interventions designed to improve treatment linkage and engagement in Dayton, Ohio. The value of a client's time accounted for the largest component of total cost (more than 59%). The cost per visit for outpatient clients ranged from $19 for outpatient methadone to $38 for intensive outpatient/aftercare treatment. The average cost per day of treatment for inpatient clients was $235. Policy makers and treatment providers now have a broader view of the opportunity cost of addiction treatment and can use this information to support initiatives for improved treatment access and delivery.

Entities:  

Mesh:

Year:  2009        PMID: 19574000      PMCID: PMC2737263          DOI: 10.1016/j.drugalcdep.2009.05.014

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  27 in total

1.  Long-term alcoholism treatment costs.

Authors:  A C Goodman; E Nishiura; J R Hankin; H D Holder; J M Tilford
Journal:  Med Care Res Rev       Date:  1996-12       Impact factor: 3.929

2.  Economic costs, cost-effectiveness, financing, and community-based drug treatment.

Authors: 
Journal:  NIDA Res Monogr       Date:  1991

3.  Estimating the economic cost of substance abuse treatment.

Authors:  M T French; K A McGeary
Journal:  Health Econ       Date:  1997 Sep-Oct       Impact factor: 3.046

4.  A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP).

Authors:  M T French; L J Dunlap; G A Zarkin; K A McGeary; A T McLellan
Journal:  J Subst Abuse Treat       Date:  1997 Sep-Oct

Review 5.  Estimating costs of mental health and substance abuse coverage.

Authors:  R G Frank; T G McGuire
Journal:  Health Aff (Millwood)       Date:  1995       Impact factor: 6.301

6.  Financing and cost of standard and enhanced methadone treatment.

Authors:  C J Bradley; M T French; J V Rachal
Journal:  J Subst Abuse Treat       Date:  1994 Sep-Oct

Review 7.  Valuing patient and caregiver time: a review of the literature.

Authors:  Jennifer E Tranmer; Denise N Guerriere; Wendy J Ungar; Peter C Coyte
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 8.  Drug treatment services: funding and admissions.

Authors:  W Butynski
Journal:  NIDA Res Monogr       Date:  1991

9.  The economic burden of mental illness.

Authors:  D P Rice; S Kelman; L S Miller
Journal:  Hosp Community Psychiatry       Date:  1992-12

10.  Service-level costing of drug abuse treatment.

Authors:  D W Anderson; B J Bowland; W S Cartwright; G Bassin
Journal:  J Subst Abuse Treat       Date:  1998 May-Jun
View more
  5 in total

1.  Economic analysis of a multi-site prevention program: assessment of program costs and characterizing site-level variability.

Authors:  Phaedra S Corso; Justin B Ingels; Steven M Kogan; E Michael Foster; Yi-Fu Chen; Gene H Brody
Journal:  Prev Sci       Date:  2013-10

2.  The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation.

Authors:  Bruce R Schackman; Jared A Leff; Michael Botsko; David A Fiellin; Fredrick L Altice; P Todd Korthuis; Nancy Sohler; Linda Weiss; James E Egan; Julie Netherland; Jonathan Gass; Ruth Finkelstein
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

3.  The cost of providing methadone maintenance treatment in Ontario, Canada.

Authors:  Gregory S Zaric; Andrew W Brennan; Michael Varenbut; Jeff M Daiter
Journal:  Am J Drug Alcohol Abuse       Date:  2012-07-11       Impact factor: 3.829

4.  The Key to Individualized Addiction Treatment is Comprehensive Assessment and Monitoring of Symptoms and Behavioral Change.

Authors:  Thomas F Hilton; Paul A Pilkonis
Journal:  Behav Sci (Basel)       Date:  2015-10-30

5.  Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.

Authors:  Cora L Bernard; Douglas K Owens; Jeremy D Goldhaber-Fiebert; Margaret L Brandeau
Journal:  PLoS Med       Date:  2017-05-24       Impact factor: 11.613

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.